{
    "clinical_study": {
        "@rank": "95580", 
        "arm_group": [
            {
                "arm_group_label": "A/17/turkey/Turkey/05/133 (H5N2)", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate safety and reactogenicity of live attenuated\n      influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO,\n      in Thailand to previously healthy Thais."
        }, 
        "brief_title": "Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers", 
        "condition": "Preventive Avian Flu", 
        "condition_browse": {
            "mesh_term": [
                "Influenza in Birds", 
                "Influenza, Human"
            ]
        }, 
        "detailed_description": {
            "textblock": "It is a phase I randomized placebo controlled trial (vaccine and placebo ratio of 2:1). A\n      phase II study is planned to be conducted following review of results of this phase.\n\n      Phase I: It is a double blind randomized placebo controlled trial involving 24 participants\n      age 18-49 years (16 will receive vaccines and 8 will receive placebo). All will be admitted\n      in the isolation ward for 10-14 days after each immunization mainly for safety assessment.\n      Two doses of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133\n      (H5N2) will be given by intranasal route 21 days apart. Each group of 4 participants will be\n      immunized at a time at 30-60 mins interval. All participants will be followed 21 days after\n      each immunization. Total follow up is 60 day."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy\n\n          -  Age 18-49  years old\n\n          -  Having Thai ID  card or equivalent\n\n          -  Are seronegative to the specific H5 influenza virus determined by antibody titer less\n             than 1:40 by HAI test to the corresponding antigen.\n\n          -  Anti HIV - Negative\n\n          -  All hematology & biochemistry and urine analysis are within normal range or of no\n             clinical significance (not more than 1.5 times of normal value)\n\n          -  Able to read and write and sign written informed consent.\n\n        Exclusion Criteria:\n\n          -  Known history of egg allergy\n\n          -  Having had recently influenza infection confirmed as H5\n\n          -  History of bronchial asthma\n\n          -  History of chronic lung diseases\n\n          -  History of chronic rhinitis\n\n          -  History of immunodeficiency state\n\n          -  History of immunosuppression\n\n          -  History of heavy smoking (more than 5 rolls per day)\n\n          -  History of alcoholic (pure drink 200 ml per day)\n\n          -  Acute infectious and noninfectious diseases (within 2 weeks)\n\n          -  Exacerbation of chronic diseases or cancer or HIV positives\n\n          -  Anamnestic leukocytosis, hepatitis B and C positives\n\n          -  The volunteers who have been taking immunoglobulin products or have had a blood\n             transfusion during past three months before the beginning of the experiment\n\n          -  Participation in other research study or stop participant less than 1 month\n\n          -  Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding\n\n          -  Any concomitant medication with Aspirin\n\n          -  The volunteers who have family members with immunodeficiency\n\n          -  Poultry workers\n\n          -  Have undertaken international travel within the one week prior to immunization"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01656356", 
            "org_study_id": "GPO AVIAN FLU Vaccine-V02"
        }, 
        "intervention": [
            {
                "arm_group_label": "A/17/turkey/Turkey/05/133 (H5N2)", 
                "intervention_name": "Avian Flu Vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Avian Flu", 
            "H5N2"
        ], 
        "lastchanged_date": "August 7, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Bangkok", 
                    "country": "Thailand", 
                    "zip": "10400"
                }, 
                "name": "Faculty of Tropical Medicine"
            }
        }, 
        "location_countries": {
            "country": "Thailand"
        }, 
        "official_title": "Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Thailand: Ethical Committee", 
                "Thailand: Food and Drug Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01656356"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mahidol University", 
            "investigator_full_name": "Punnee Pitisuttithum", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mahidol University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mahidol University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2012", 
        "study_design": "N/A", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}